The Oral NK1 Antagonist Aprepitant for Prevention of Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
- 1 January 2005
- journal article
- Published by Springer Science and Business Media LLC in American Journal of Cancer
- Vol. 4 (1), 35-48
- https://doi.org/10.2165/00024669-200504010-00003
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study GroupJournal of Clinical Oncology, 2003
- Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonistsEuropean Journal Of Cancer, 2003
- Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomitingCancer, 2003
- Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869Cancer, 2002
- Potential of Substance P Antagonists as AntiemeticsDrugs, 2000
- The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferretsNeuropharmacology, 2000
- Neuropharmacology of emesis and its relevance to anti-emetic therapySupportive Care in Cancer, 1998
- Effect of postchemotherapy nausea and vomiting on health-related quality of lifeSupportive Care in Cancer, 1997
- Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferretsNeuropharmacology, 1996
- Participation of Serotonin on Early and Delayed Emesis Induced by Initial and Subsequent Cycles of Cisplatinum‐Based Chemotherapy: Effects of AntiemeticsThe Journal of Clinical Pharmacology, 1993